ClinicalTrials.gg
CompletedNCT00163215Updated Dec 19, 2012Results posted

Growth Retardation In Children With Special Pathological Conditions Or Disease

A Phase 3 interventional study of Somatropin in Endocrine System Diseases, sponsored by Pfizer. Completed at 18 sites in France. Open to participants aged 11 Years to 13 Years. Per ClinicalTrials.gov, last updated 2012-12-19.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
46
Allocation
Non-randomized
Ages
11 Years to 13 Years
Sex
All
01

Study summary

To show an increase in annual growth rate 3 years after Visit 2. Annual growth rate in standard deviation (SD) after 3 years will be compared to growth rate before the start of GH treatment.

02

Conditions studied

  • Endocrine System Diseases
03

In context

Endocrine System Diseases

322 studies on the registry are indexed under Endocrine System Diseases; 51 are open to participants now.

This study's enrollment of 46 is below the median of 69 across 221 interventional studies indexed under Endocrine System Diseases.

Browse Endocrine System Diseases studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
11 Years to 13 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Bone age \< 13 years for a boy and \< 11 years for a girl
  • Naive child: Measured Height \< -2.5 SD for CA
  • Child currently treated by GH

Exclusion criteria

Exclusion Criteria:

  • Idiopathic short stature
  • Syndrome known to be associated with an increased risk of cancer e.g. family history of adenomatous polyposis
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Somatropin

    Drug: Somatropin

Interventions

  • Adapted dosage based on IGF 1 level and weight Form: liquid; Dosage and Frequency: from 0.0033mg/kg/day to 0.0067 mg/kg/day; Duration: 3 years

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Annual Growth Rate Standard Deviation Score (SDS) for Chronological Age (CA) at Month 36 in Intent-to-Treat (ITT) Population

    Change in annual growth rate (AGR) standard deviation score (SDS) for chronological age (CA) derived by subtracting AGR SDS CA at baseline from each time point (Yx) value. AGR at Yx= (height Yx-height Y\[x-1\])/(\[date of Yx-date of Y{x-1}\]/365.25). AGR as SDS calculated using Sempe reference means and standard deviations (SD) for growth rate. AGR SDS CA (for both baseline and Yx)= (AGR-reference mean for growth rate CA)/reference SD for growth rate CA. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12. SDS indicates how similar participant was to reference population.

    Time frame: Baseline, Month 36

  2. Change From Baseline in Annual Growth Rate Standard Deviation Score (SDS) for Chronological Age (CA) at Month 36 in Per-Protocol (PP) Population

    Change in annual growth rate (AGR) standard deviation score (SDS) for chronological age (CA) derived by subtracting AGR SDS CA at baseline from each time point (Yx) value. AGR at Yx= (height Yx-height Y\[x-1\])/(\[date of Yx-date of Y{x-1}\]/365.25). AGR as SDS calculated using Sempe reference means and standard deviations (SD) for growth rate. AGR SDS CA (for both baseline and Yx)= (AGR-reference mean for growth rate CA)/reference SD for growth rate CA. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12. SDS indicates how similar participant was to reference population.

    Time frame: Baseline, Month 36

Secondary outcomes

  1. Change From Baseline in Annual Growth Rate at Month 12, Month 24 and Month 36 in ITT Population

    Change in AGR at Yx was derived by subtracting AGR at baseline from Yx value. Annual growth rate was calculated each year and rescaled to 1 year if the interval between Yx and Y\[x-1\] was not 365 days, as long as a participant remained in the study. AGR at Yx was calculated using the previous height measurements (Y\[x-1\]) and height recorded at Yx (AGR Yx = \[height Yx-height Y{x-1}\] / (\[date of Yx - date of Y{x-1}\] /365.25).

    Time frame: Baseline, Month 12, Month 24, Month 36

  2. Change From Baseline in Annual Growth Rate at Month 12, Month 24, Month 36 in PP Population

    Change in AGR at Yx was derived by subtracting AGR at baseline from Yx value. Annual growth rate was calculated each year and rescaled to 1 year if the interval between Yx and Y\[x-1\] was not 365 days, as long as a participant remained in the study. AGR at Yx was calculated using the previous height measurements (Y\[x-1\]) and height recorded at Yx (AGR Yx = \[height Yx-height Y{x-1}\] / (\[date of Yx - date of Y{x-1}\] /365.25).

    Time frame: Baseline, Month 12, Month 24, Month 36

  3. Height

    Height was measured using a wall mounted device (example, Harpenden stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded.

    Time frame: Baseline, Month 12, Month 24, Month 36

  4. Change From Baseline in Height at Month 12, Month 24 and Month 36

    Height was measured using a wall mounted device (example, Harpenden stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded.

    Time frame: Baseline, Month 12, Month 24, Month 36

  5. Mean Height Standard Deviation Score (SDS) for Chronological Age (CA)

    Height was measured using a wall mounted device (example, Harpenden stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded. Height SDS CA Yx = (height Yx - reference mean for CA Yx) / reference SD for CA Yx. Height in SDS was calculated using Sempe reference means and SD for height. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12. SDS indicates how similar the participant was to the reference population.

    Time frame: Baseline, Month 12, Month 24, Month 36

  6. Change From Baseline in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Month 12, Month 24 and Month 36

    Change in height SDS CA was derived by subtracting height SDS CA at baseline from Yx value. Height SDS CA (for both baseline and Yx) = (height - reference mean for CA)/reference SD for CA. Height in SDS was calculated using Sempe reference means and SD for height. CA calculated as integer (Date of height measurement - Date of birth)/365.25\*12. SDS indicates how similar the participant was to the reference population.

    Time frame: Baseline, Month 12, Month 24, Month 36

  7. Mean Height Standard Deviation Score (SDS) for Bone Age (BA)

    Height SDS BA Yx = (height Yx - reference mean for BA Yx) / reference SD for BA Yx. Height in SDS was calculated using Sempe reference means and SD for height. BA was estimated locally using an X-ray from the left wrist and hand. SDS indicates how similar the participant was to the reference population.

    Time frame: Baseline, Month 12, Month 24, Month 36

  8. Change From Baseline in Height Standard Deviation Score (SDS) for Bone Age (BA) at Month 12, Month 24 and Month 36

    Change in height SDS BA was derived by subtracting height SDS BA at baseline from Yx value. Height SDS BA (for both baseline and Yx) = (height-reference mean for BA)/reference SD for BA. Height in SDS was calculated using Sempe reference means and SD for height. BA was estimated locally using an X-ray from the left wrist and hand. SDS indicates how similar the participant was to the reference population.

    Time frame: Baseline, Month 12, Month 24, Month 36

  9. Change From Baseline in Annual Growth Rate Standard Deviation Score (SDS) for Chronological Age (CA) at Month 12 and Month 24 in ITT Population

    Change in AGR SDS for CA derived by subtracting AGR SDS CA at baseline from Yx value. AGR at Yx= (height Yx-height Y\[x-1\])/(\[date of Yx-date of Y{x-1}\]/365.25). AGR as SDS calculated using Sempe reference means and standard deviations (SD) for growth rate. AGR SDS CA (for both baseline and Yx)= (AGR-reference mean for growth rate CA)/reference SD for growth rate CA. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12. SDS indicates how similar participant was to reference population.

    Time frame: Baseline, Month 12, Month 24

  10. Change From Baseline in Annual Growth Rate Standard Deviation Score (SDS) for Chronological Age (CA) at Month 12 and Month 24 in PP Population

    Change in annual growth rate (AGR) standard deviation score (SDS) for chronological age (CA) derived by subtracting AGR SDS CA at baseline from each time point (Yx) value. AGR at Yx= (height Yx-height Y\[x-1\])/(\[date of Yx-date of Y{x-1}\]/365.25). AGR as SDS calculated using Sempe reference means and standard deviations (SD) for growth rate. AGR SDS CA (for both baseline and Yx)= (AGR-reference mean for growth rate CA)/reference SD for growth rate CA. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12. SDS indicates how similar participant was to reference population.

    Time frame: Baseline, Month 12, Month 24

  11. Mean Growth Rate Standard Deviation Score (SDS) for Bone Age (BA)

    AGR at Yx was derived by subtracting AGR at baseline from Yx value. AGR was calculated each year and rescaled to 1 year if the interval between Yx and Y\[x-1\] was not 365 days, as long as a participant remained in the study. AGR at Yx = \[height Yx-height Y{x-1}\] / (\[date of Yx - date of Y{x-1}\] /365.25). GR in SDS was calculated using Sempe reference means and SD for growth. BA was estimated locally using an X-ray from the left wrist and hand. SDS indicates how similar the participant was to the reference population.

    Time frame: Month 12, Month 24, Month 36

  12. Body Mass Index (BMI)

    BMI was used to measure body fat based on height and weight. It was calculated as body weight (kilogram) divided by the height (meter) squared.

    Time frame: Baseline, Month 12, Month 24, Month 36

  13. Change From Baseline in Body Mass Index (BMI) at Month 12, Month 24 and Month 36

    BMI was used to measure body fat based on height and weight. It was calculated as body weight (kilogram) divided by the height (meter) squared.

    Time frame: Baseline, Month 12, Month 24, Month 36

  14. Change From Baseline in Bone Age (BA) at Month 12, Month 24 and Month 36

    BA was estimated locally using an X-ray from the left wrist and hand.

    Time frame: Baseline, Month 12, Month 24, Month 36

  15. Ratio of Bone Age (BA) to Chronological Age (CA)

    BA was estimated locally using an X-ray from the left wrist and hand. CA at the date of corresponding X-ray (Date of X-ray - Date of birth)/365.25. Ratio of BA/CA at each annual study visit was calculated.

    Time frame: Baseline, Month 12, Month 24, Month 36

07

Results

Posted Dec 19, 2012

Participant flow

Participant flow — Overall Study
MilestoneGenotonorm
Started46
Completed31
Not completed15
Withdrew: Lack of efficacy3
Withdrew: Withdrawal by subject5
Withdrew: Other7

Outcome measures

PrimaryChange From Baseline in Annual Growth Rate Standard Deviation Score (SDS) for Chronological Age (CA) at Month 36 in Intent-to-Treat (ITT) Population

Change in annual growth rate (AGR) standard deviation score (SDS) for chronological age (CA) derived by subtracting AGR SDS CA at baseline from each time point (Yx) value. AGR at Yx= (height Yx-height Y\[x-1\])/(\[date of Yx-date of Y{x-1}\]/365.25). AGR as SDS calculated using Sempe reference means and standard deviations (SD) for growth rate. AGR SDS CA (for both baseline and Yx)= (AGR-reference mean for growth rate CA)/reference SD for growth rate CA. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12. SDS indicates how similar participant was to reference population.

Time frame:
Baseline, Month 36
Reported as:
Mean · SDS
Change From Baseline in Annual Growth Rate Standard Deviation Score (SDS) for Chronological Age (CA) at Month 36 in Intent-to-Treat (ITT) Population
SDSGenotonorm
Baseline (n = 42)-1.29 ± 1.79
Change at Month 36 (n = 26)2.36 ± 1.98
PrimaryChange From Baseline in Annual Growth Rate Standard Deviation Score (SDS) for Chronological Age (CA) at Month 36 in Per-Protocol (PP) Population

Change in annual growth rate (AGR) standard deviation score (SDS) for chronological age (CA) derived by subtracting AGR SDS CA at baseline from each time point (Yx) value. AGR at Yx= (height Yx-height Y\[x-1\])/(\[date of Yx-date of Y{x-1}\]/365.25). AGR as SDS calculated using Sempe reference means and standard deviations (SD) for growth rate. AGR SDS CA (for both baseline and Yx)= (AGR-reference mean for growth rate CA)/reference SD for growth rate CA. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12. SDS indicates how similar participant was to reference population.

Time frame:
Baseline, Month 36
Reported as:
Mean · SDS
Change From Baseline in Annual Growth Rate Standard Deviation Score (SDS) for Chronological Age (CA) at Month 36 in Per-Protocol (PP) Population
SDSGenotonorm
Baseline (n = 14)-1.98 ± 1.06
Change at Month 36 (n = 12)2.70 ± 2.02
SecondaryChange From Baseline in Annual Growth Rate at Month 12, Month 24 and Month 36 in ITT Population

Change in AGR at Yx was derived by subtracting AGR at baseline from Yx value. Annual growth rate was calculated each year and rescaled to 1 year if the interval between Yx and Y\[x-1\] was not 365 days, as long as a participant remained in the study. AGR at Yx was calculated using the previous height measurements (Y\[x-1\]) and height recorded at Yx (AGR Yx = \[height Yx-height Y{x-1}\] / (\[date of Yx - date of Y{x-1}\] /365.25).

Time frame:
Baseline, Month 12, Month 24, Month 36
Reported as:
Mean · centimeter per year (cm/year)
Change From Baseline in Annual Growth Rate at Month 12, Month 24 and Month 36 in ITT Population
centimeter per year (cm/year)Genotonorm
Baseline (n = 42)4.5 ± 1.8
Change at Month 12 (n = 36)3.3 ± 2.9
Change at Month 24 (n = 35)2.5 ± 2.7
Change at Month 36 (n = 26)2.0 ± 2.0
SecondaryChange From Baseline in Annual Growth Rate at Month 12, Month 24, Month 36 in PP Population

Change in AGR at Yx was derived by subtracting AGR at baseline from Yx value. Annual growth rate was calculated each year and rescaled to 1 year if the interval between Yx and Y\[x-1\] was not 365 days, as long as a participant remained in the study. AGR at Yx was calculated using the previous height measurements (Y\[x-1\]) and height recorded at Yx (AGR Yx = \[height Yx-height Y{x-1}\] / (\[date of Yx - date of Y{x-1}\] /365.25).

Time frame:
Baseline, Month 12, Month 24, Month 36
Reported as:
Mean · cm/year
Change From Baseline in Annual Growth Rate at Month 12, Month 24, Month 36 in PP Population
cm/yearGenotonorm
Baseline (n = 14)4.0 ± 1.0
Change at Month 12 (n = 14)4.0 ± 1.0
Change at Month 24 (n = 14)2.5 ± 1.3
Change at Month 36 (n = 12)1.8 ± 1.1
SecondaryHeight

Height was measured using a wall mounted device (example, Harpenden stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded.

Time frame:
Baseline, Month 12, Month 24, Month 36
Reported as:
Mean · cm
Height
cmGenotonorm
Baseline (n = 44)123.9 ± 17.3
Month 12 (n = 39)130.3 ± 17.5
Month 24 (n = 39)137.8 ± 16.9
Month 36 (n = 27)143.5 ± 15.8
SecondaryChange From Baseline in Height at Month 12, Month 24 and Month 36

Height was measured using a wall mounted device (example, Harpenden stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded.

Time frame:
Baseline, Month 12, Month 24, Month 36
Reported as:
Mean · cm
Change From Baseline in Height at Month 12, Month 24 and Month 36
cmGenotonorm
Change at Month 12 (n = 39)7.7 ± 2.1
Change at Month 24 (n = 39)14.9 ± 3.4
Change at Month 36 (n = 27)22.3 ± 3.7
SecondaryMean Height Standard Deviation Score (SDS) for Chronological Age (CA)

Height was measured using a wall mounted device (example, Harpenden stadiometer). The standing height of the participant was measured two times and the mean of these measurements was recorded. Height SDS CA Yx = (height Yx - reference mean for CA Yx) / reference SD for CA Yx. Height in SDS was calculated using Sempe reference means and SD for height. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12. SDS indicates how similar the participant was to the reference population.

Time frame:
Baseline, Month 12, Month 24, Month 36
Reported as:
Mean · SDS
Mean Height Standard Deviation Score (SDS) for Chronological Age (CA)
SDSGenotonorm
Baseline (n = 44)-2.84 ± 0.91
Month 12 (n = 39)-2.42 ± 0.98
Month 24 (n = 39)-2.09 ± 1.08
Month 36 (n = 27)-1.72 ± 0.96
SecondaryChange From Baseline in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Month 12, Month 24 and Month 36

Change in height SDS CA was derived by subtracting height SDS CA at baseline from Yx value. Height SDS CA (for both baseline and Yx) = (height - reference mean for CA)/reference SD for CA. Height in SDS was calculated using Sempe reference means and SD for height. CA calculated as integer (Date of height measurement - Date of birth)/365.25\*12. SDS indicates how similar the participant was to the reference population.

Time frame:
Baseline, Month 12, Month 24, Month 36
Reported as:
Mean · SDS
Change From Baseline in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Month 12, Month 24 and Month 36
SDSGenotonorm
Change at Month 12 (n = 39)0.41 ± 0.42
Change at Month 24 (n = 39)0.81 ± 0.60
Change at Month 36 (n = 27)1.03 ± 0.62
SecondaryMean Height Standard Deviation Score (SDS) for Bone Age (BA)

Height SDS BA Yx = (height Yx - reference mean for BA Yx) / reference SD for BA Yx. Height in SDS was calculated using Sempe reference means and SD for height. BA was estimated locally using an X-ray from the left wrist and hand. SDS indicates how similar the participant was to the reference population.

Time frame:
Baseline, Month 12, Month 24, Month 36
Reported as:
Mean · SDS
Mean Height Standard Deviation Score (SDS) for Bone Age (BA)
SDSGenotonorm
Baseline (n = 35)-0.71 ± 1.52
Month 12 (n = 32)-0.55 ± 1.68
Month 24 (n = 32)-0.49 ± 1.77
Month 36 (n = 20)-0.30 ± 1.46
SecondaryChange From Baseline in Height Standard Deviation Score (SDS) for Bone Age (BA) at Month 12, Month 24 and Month 36

Change in height SDS BA was derived by subtracting height SDS BA at baseline from Yx value. Height SDS BA (for both baseline and Yx) = (height-reference mean for BA)/reference SD for BA. Height in SDS was calculated using Sempe reference means and SD for height. BA was estimated locally using an X-ray from the left wrist and hand. SDS indicates how similar the participant was to the reference population.

Time frame:
Baseline, Month 12, Month 24, Month 36
Reported as:
Mean · SDS
Change From Baseline in Height Standard Deviation Score (SDS) for Bone Age (BA) at Month 12, Month 24 and Month 36
SDSGenotonorm
Change at Month 12 (n = 28)-0.05 ± 1.04
Change at Month 24 (n = 27)0.06 ± 1.36
Change at Month 36 (n = 17)0.05 ± 1.32
SecondaryChange From Baseline in Annual Growth Rate Standard Deviation Score (SDS) for Chronological Age (CA) at Month 12 and Month 24 in ITT Population

Change in AGR SDS for CA derived by subtracting AGR SDS CA at baseline from Yx value. AGR at Yx= (height Yx-height Y\[x-1\])/(\[date of Yx-date of Y{x-1}\]/365.25). AGR as SDS calculated using Sempe reference means and standard deviations (SD) for growth rate. AGR SDS CA (for both baseline and Yx)= (AGR-reference mean for growth rate CA)/reference SD for growth rate CA. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12. SDS indicates how similar participant was to reference population.

Time frame:
Baseline, Month 12, Month 24
Reported as:
Mean · SDS
Change From Baseline in Annual Growth Rate Standard Deviation Score (SDS) for Chronological Age (CA) at Month 12 and Month 24 in ITT Population
SDSGenotonorm
Change at Month 12 (n = 36)3.23 ± 2.66
Change at Month 24 (n = 35)2.62 ± 2.05
SecondaryChange From Baseline in Annual Growth Rate Standard Deviation Score (SDS) for Chronological Age (CA) at Month 12 and Month 24 in PP Population

Change in annual growth rate (AGR) standard deviation score (SDS) for chronological age (CA) derived by subtracting AGR SDS CA at baseline from each time point (Yx) value. AGR at Yx= (height Yx-height Y\[x-1\])/(\[date of Yx-date of Y{x-1}\]/365.25). AGR as SDS calculated using Sempe reference means and standard deviations (SD) for growth rate. AGR SDS CA (for both baseline and Yx)= (AGR-reference mean for growth rate CA)/reference SD for growth rate CA. CA calculated as integer (Date of height measurement-Date of birth)/365.25\*12. SDS indicates how similar participant was to reference population.

Time frame:
Baseline, Month 12, Month 24
Reported as:
Mean · SDS
Change From Baseline in Annual Growth Rate Standard Deviation Score (SDS) for Chronological Age (CA) at Month 12 and Month 24 in PP Population
SDSGenotonorm
Change at Month 12 (n = 14)4.40 ± 2.12
Change at Month 24 (n = 14)2.97 ± 1.68
SecondaryMean Growth Rate Standard Deviation Score (SDS) for Bone Age (BA)

AGR at Yx was derived by subtracting AGR at baseline from Yx value. AGR was calculated each year and rescaled to 1 year if the interval between Yx and Y\[x-1\] was not 365 days, as long as a participant remained in the study. AGR at Yx = \[height Yx-height Y{x-1}\] / (\[date of Yx - date of Y{x-1}\] /365.25). GR in SDS was calculated using Sempe reference means and SD for growth. BA was estimated locally using an X-ray from the left wrist and hand. SDS indicates how similar the participant was to the reference population.

Time frame:
Month 12, Month 24, Month 36
Reported as:
Mean · SDS
Mean Growth Rate Standard Deviation Score (SDS) for Bone Age (BA)
SDSGenotonorm
Month 12 (n = 28)1.06 ± 1.57
Month 24 (n = 25)0.46 ± 1.15
Month 36 (n = 19)-0.01 ± 1.19
SecondaryBody Mass Index (BMI)

BMI was used to measure body fat based on height and weight. It was calculated as body weight (kilogram) divided by the height (meter) squared.

Time frame:
Baseline, Month 12, Month 24, Month 36
Reported as:
Mean · kilogram per square meter (kg/m^2)
Body Mass Index (BMI)
kilogram per square meter (kg/m^2)Genotonorm
Baseline (n = 44)16.57 ± 2.37
Month 12 (n = 39)16.96 ± 2.64
Month 24 (n = 39)17.59 ± 2.69
Month 36 (n = 27)17.67 ± 2.08
SecondaryChange From Baseline in Body Mass Index (BMI) at Month 12, Month 24 and Month 36

BMI was used to measure body fat based on height and weight. It was calculated as body weight (kilogram) divided by the height (meter) squared.

Time frame:
Baseline, Month 12, Month 24, Month 36
Reported as:
Mean · kg/m^2
Change From Baseline in Body Mass Index (BMI) at Month 12, Month 24 and Month 36
kg/m^2Genotonorm
Change at Month 12 (n = 39)0.52 ± 1.01
Change at Month 24 (n = 39)1.30 ± 1.35
Change at Month 36 (n = 27)1.89 ± 1.61
SecondaryChange From Baseline in Bone Age (BA) at Month 12, Month 24 and Month 36

BA was estimated locally using an X-ray from the left wrist and hand.

Time frame:
Baseline, Month 12, Month 24, Month 36
Reported as:
Mean · years
Change From Baseline in Bone Age (BA) at Month 12, Month 24 and Month 36
yearsGenotonorm
Baseline (n = 40)8.70 ± 3.28
Change at Month 12 (n = 28)1.69 ± 0.90
Change at Month 24 (n = 28)2.60 ± 0.97
Change at Month 36 (n = 21)4.04 ± 1.09
SecondaryRatio of Bone Age (BA) to Chronological Age (CA)

BA was estimated locally using an X-ray from the left wrist and hand. CA at the date of corresponding X-ray (Date of X-ray - Date of birth)/365.25. Ratio of BA/CA at each annual study visit was calculated.

Time frame:
Baseline, Month 12, Month 24, Month 36
Reported as:
Mean · ratio
Ratio of Bone Age (BA) to Chronological Age (CA)
ratioGenotonorm
Baseline (n = 40)0.79 ± 0.15
Month 12 (n = 30)0.83 ± 0.15
Month 24 (n = 32)0.85 ± 0.12
Month 36 (n = 23)0.89 ± 0.14

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Genotonorm—4/46 (8.7%)21/46 (45.7%)
Most frequent serious events
Most frequent serious events
EventGenotonorm
CryptorchismCongenital, familial and genetic disorders1/46
LaryngitisInfections and infestations1/46
Staphylococcal infectionInfections and infestations1/46
Staphylococcal sepsisInfections and infestations1/46
Viral infectionInfections and infestations1/46
Head injuryInjury, poisoning and procedural complications1/46
Weight decreasedInvestigations1/46
Histiocytosis haematophagicNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/46
Most frequent other events
Showing 10 of 34
Most frequent other events
EventGenotonorm
HeadacheNervous system disorders5/46
DiarrhoeaGastrointestinal disorders2/46
Oral herpesInfections and infestations2/46
Bronchopulmonary aspergillosis allergicInfections and infestations1/46
InfluenzaInfections and infestations1/46
LaryngitisInfections and infestations1/46
NasopharyngitisInfections and infestations1/46
TracheitisInfections and infestations1/46
Joint injuryInjury, poisoning and procedural complications1/46
Ligament sprainInjury, poisoning and procedural complications1/46

Baseline characteristics

Age Continuous
Age Continuous(years)Genotonorm
Mean10.3 ± 3.6
Sex: Female, Male
Sex: Female, Male(Participants)Genotonorm
Female12
Male34
08

Study locations

18 sites
  • Pfizer Investigational Site
    Annemasse Cedex, 74107, France
  • Pfizer Investigational Site
    Besancon, 25030, France
  • Pfizer Investigational Site
    Bordeaux, 33000, France
  • Pfizer Investigational Site
    Bordeaux, 33076, France
  • Pfizer Investigational Site
    Bron Cedex, 69677, France
  • Pfizer Investigational Site
    Dijon, 21000, France
  • Pfizer Investigational Site
    Grenoble Cedex, 38043, France
  • Pfizer Investigational Site
    Lorient, 56100, France
  • Pfizer Investigational Site
    Lyon Cedex 05, 69322, France
  • Pfizer Investigational Site
    Marseille, 13385, France
  • Pfizer Investigational Site
    Montpellier, 34059, France
  • Pfizer Investigational Site
    Paris, 75015, France
  • Pfizer Investigational Site
    Paris, 75019, France
  • Pfizer Investigational Site
    Paris, 75571, France
  • Pfizer Investigational Site
    Paris, 75674 Cedex, France
  • Pfizer Investigational Site
    PRINGY Cedex, 74374, France
  • Pfizer Investigational Site
    Toulouse Cedex, 31026, France
  • Pfizer Investigational Site
    Vandoeuvre Les Nancy Cedex, 54511, France
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2012, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 13, 2005
Start
Jan 2005
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Results first posted
Dec 19, 2012
Last update
Dec 19, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00163215
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 13, 2005
Start date
Jan 2005
Primary completion
Oct 2011
Completion
Oct 2011
Results posted
Dec 19, 2012
Last update
Dec 19, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion